# A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

> **NCT06526923** · PHASE1,PHASE2 · RECRUITING · sponsor: **Spirovant Sciences, Inc.** · enrollment: 15 (estimated)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **COMBINATION_PRODUCT:** SP-101 and doxorubicin Cohort 1
- **COMBINATION_PRODUCT:** SP-101 and doxorubicin Cohort 2

## Key facts

- **NCT ID:** NCT06526923
- **Lead sponsor:** Spirovant Sciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-16
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06526923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06526923, "A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06526923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*